Silexion Therapeutics Corp. Files 8-K
Ticker: SLXNW · Form: 8-K · Filed: Sep 4, 2025 · CIK: 2022416
Sentiment: neutral
Topics: corporate-update, name-change
Related Tickers: SLXN
TL;DR
Silexion Therapeutics (fka Biomotion) filed an 8-K on 9/4/25 - likely corporate updates.
AI Summary
Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on September 4, 2025, reporting on events that occurred on the same date. The filing indicates a change in the company's name and potentially other corporate actions, as it is listed under Regulation FD Disclosure and Financial Statements and Exhibits.
Why It Matters
This filing signals significant corporate activity for Silexion Therapeutics, including a recent name change from Biomotion Sciences, which may impact investors' understanding of the company's current operations and strategic direction.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for corporate updates and does not appear to contain immediate negative financial news.
Key Players & Entities
- Silexion Therapeutics Corp (company) — Registrant
- Biomotion Sciences (company) — Former company name
- September 4, 2025 (date) — Date of report
FAQ
What specific events are detailed in the 8-K filing by Silexion Therapeutics Corp. on September 4, 2025?
The filing is categorized under 'Regulation FD Disclosure' and 'Financial Statements and Exhibits', suggesting it pertains to significant corporate events or disclosures, though the specific details are not provided in the header information.
When did Silexion Therapeutics Corp. change its name from Biomotion Sciences?
The filing indicates the 'DATE OF NAME CHANGE' was May 6, 2024.
What is Silexion Therapeutics Corp.'s primary business according to its SIC code?
Silexion Therapeutics Corp.'s Standard Industrial Classification (SIC) code is 2836, which corresponds to 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)'.
Where is Silexion Therapeutics Corp. headquartered?
Silexion Therapeutics Corp.'s principal executive offices are located at 12 Abba Hillel Road, Ramat-Gan, Israel.
What is the SEC file number for Silexion Therapeutics Corp.?
The SEC file number for Silexion Therapeutics Corp. is 001-42253.
Filing Stats: 541 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2025-09-04 17:29:03
Key Financial Figures
- $0.0135 — registered Ordinary Shares, par value $0.0135 per share SLXN The Nasdaq Stock Mar
- $1,552.50 — Ordinary Shares at an exercise price of $1,552.50 per share SLXNW The Nasdaq Stock Ma
Filing Documents
- zk2533756.htm (8-K) — 49KB
- exhibit_99-1.htm (EX-99.1) — 14KB
- image0.jpg (GRAPHIC) — 27KB
- 0001178913-25-003248.txt ( ) — 276KB
- slxn-20250904.xsd (EX-101.SCH) — 5KB
- slxn-20250904_def.xml (EX-101.DEF) — 18KB
- slxn-20250904_lab.xml (EX-101.LAB) — 27KB
- slxn-20250904_pre.xml (EX-101.PRE) — 20KB
- zk2533756_htm.xml (XML) — 6KB
01
Item 7.01 Regulation FD Disclosure. On September 4, 2025, Silexion Therapeutics Corp issued a press release entitled "Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL 204." A copy of the press release is furnished with this Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information in Item 7.01 of this Form 8-K, including the information in the press release furnished pursuant to this Item 7.01 of Form 8-K, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this Form 8-K, including the information in the press release, shall not be deemed to be incorporated by reference in the filings of the registrant under the Securities Act of 1933, as amended.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits 99.1 Press Release dated September 4, 2025 104 Cover Page Interactive Data File (formatted in Inline XBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SILEXION THERAPEUTICS CORP Date: September 4, 2025 By: /s/ Ilan Hadar Name: Ilan Hadar Title: Chief Executive Officer